EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Fecal Microbiota Transplantation in Colorectal Cancer: From Immune Regulation to Immunotherapy

Xin Yang iD, Xiaoqin Ge, Shengping Gong, Ting Zhu, Chao Ni, Ruishuang Ma, Qingsong Tao

Cancers · 22.10.2026 · 18 (21) · 3426

DOI: 10.3390/cancers18213426 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 22.10.2026. Verfasst von Xin Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy and Chemotherapy, The First Affiliated Hospital of Ningbo University, Ningbo 315211, China. Die Arbeit nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai YRD Foundation for Innovation in Health Industry.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gut microbiome influences colorectal cancer (CRC) progression and responses to immune checkpoint inhibitors (ICIs), with immunotherapy resistance remaining a major challenge in microsatellite-stable/mismatch repair-proficient (MSS/pMMR) CRC. This review examines the mechanisms and translational potential of fecal microbiota transplantation (FMT) in CRC immunotherapy, focusing on the interplay among microbial functions, metabolic alterations, and immune microenvironment remodeling. Current evidence suggests that FMT may influence antitumor immunity beyond restoring microbial diversity by transferring functionally relevant microbial communities, metabolic profiles, and immunomodulatory signals. These changes may affect antigen presentation, inflammatory signaling, T-cell activity, and myeloid-cell states, thereby shaping the tumor immune microenvironment and potentially modulating responses to PD-1/PD-L1 blockade. However, the clinical efficacy of FMT in CRC, the determinants of successful microbial engraftment, and the mechanisms linking donor-derived microbial functions to therapeutic outcomes remain incompletely understood. Integrating defined microbial consortia, metabolite-based interventions, and multi-omics-guided patient stratification may help advance FMT toward mechanism-driven precision microbiome therapy and inform strategies to improve CRC immunotherapy outcomes.

Schlagwörter

Stichwörter der Autor:innen

colorectal cancerfecal microbiota transplantationimmunotherapyshort-chain fatty acidstumor microenvironment

Autor:innen und Institutionen

  • Department of Radiotherapy and Chemotherapy, The First Affiliated Hospital of Ningbo University, Ningbo 315211, China.

ORCID-Profile: Xin Yang

Förderung

  • Shanghai YRD Foundation for Innovation in Health Industry

Zitieren

APA

Yang, X., Ge, X., Gong, S., Zhu, T., Ni, C., Ma, R., & Tao, Q. (2026). Fecal Microbiota Transplantation in Colorectal Cancer: From Immune Regulation to Immunotherapy. Cancers, 18(21), 3426. https://doi.org/10.3390/cancers18213426

Vancouver

Yang X, Ge X, Gong S, Zhu T, Ni C, Ma R, et al. Fecal Microbiota Transplantation in Colorectal Cancer: From Immune Regulation to Immunotherapy. Cancers. 2026;18(21):3426. doi:10.3390/cancers18213426

BibTeX
@article{Yang2026,
  author = {Yang, Xin and Ge, Xiaoqin and Gong, Shengping and Zhu, Ting and Ni, Chao and Ma, Ruishuang and Tao, Qingsong},
  title = {Fecal Microbiota Transplantation in Colorectal Cancer: From Immune Regulation to Immunotherapy},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {21},
  pages = {3426},
  doi = {10.3390/cancers18213426}
}
Kostenlos starten →